Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921328 | 1.00 | DGAT1 (0.39) | DGAT1GPR119WNT3ADDB1CRBN | |
| SCHEMBL30547503 | 1.00 | DGAT1 (0.39) | DGAT1GPR119WNT3ADDB1CRBN | |
| SCHEMBL29966472 | 1.00 | DGAT1 (0.39) | DGAT1GPR119WNT3ADDB1CRBN | |
| SCHEMBL30339115 | 0.91 | DGAT1 (0.35) | DGAT1GPR119WNT3ADDB1CRBN | |
| SCHEMBL25816413 | 0.87 | TSHR (0.37) | DDB1CRBNTSHR | |
| SCHEMBL18921529 | 0.87 | DDB1 (0.36) | GPR119WNT3ADDB1CRBNRECQL | |
| SCHEMBL29966468 | 0.87 | DDB1 (0.36) | GPR119WNT3ADDB1CRBNRECQL | |
| SCHEMBL29967034 | 0.87 | DDB1 (0.36) | GPR119WNT3ADDB1CRBNRECQL | |
| SCHEMBL28873141 | 0.87 | DDB1 (0.36) | GPR119WNT3ADDB1CRBNRECQL | |
| SCHEMBL25254326 | 0.84 | DDB1 (0.43) | DGAT1WNT3ADDB1CRBNMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709723-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233544-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | DGAT1 4175/4885GPR119 420/4885WNT3A 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.